We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.33%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.6B
AUM Growth
-$143M
Cap. Flow
-$225M
Cap. Flow %
-13.99%
Top 10 Hldgs %
36.09%
Holding
105
New
9
Increased
32
Reduced
29
Closed
12

Top Buys

Rank Stock Value
1
CAI
Caris Life Sciences
CAI
+$21.4M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$19.6M
3
OMDA
Omada Health Inc
OMDA
+$15.9M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$12.1M
5
ACLX
Arcellx
ACLX
+$11.6M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$85.4M
2
NUVL
Nuvalent
NUVL
+$24.5M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$21.8M
4
UNH icon
UnitedHealth
UNH
+$19.1M
5
LEGN icon
Legend Biotech
LEGN
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WRBY icon
101
Warby Parker
WRBY
$3.22B
– –
-835,000
Closed -$15.2M
KMTS
102
Kestra Medical Technologies
KMTS
$1.66B
– –
-145,000
Closed -$3.61M
SPRB
103
Spruce Biosciences
SPRB
$127M
– –
-34,788
Closed -$757K
NVRO
104
DELISTED
NEVRO CORP.
NVRO
– –
-800,494
Closed -$4.67M
1 2 3 4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Rock Springs Capital Management held 105 positions worth $1.6B, down 8.2% from $1.75B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $225M in Q2 2025, closing 12 positions and reducing 29 holdings. Its most notable exit was Legend Biotech, an estimated $17.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Rock Springs Capital Management opened a new position in Caris Life Sciences worth $21.2M.

  • Rock Springs Capital Management's largest Q2 2025 buy was Caris Life Sciences: 793,651 shares worth $21.2M.
  • Rock Springs Capital Management added most to Agios Pharmaceuticals in Q2 2025, an estimated $19.6M increase.
  • Rock Springs Capital Management's biggest Q2 2025 reduction was Blueprint Medicines, cutting an estimated $85.4M.
  • Rock Springs Capital Management fully exited Legend Biotech in Q2 2025, selling an estimated $17.4M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $1.6B portfolio in Q2 2025.
  • Rock Springs Capital Management opened 9 new positions and closed 12 in Q2 2025.
  • Rock Springs Capital Management's portfolio value fell 8.2% quarter-over-quarter to $1.6B.

Based on Rock Springs Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.